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Introduction {#sec005}
============

Laryngeal carcinoma is one of the most common malignancies of the head and neck \[[@pone.0188322.ref001], [@pone.0188322.ref002]\]. Supraglottic carcinoma is the dominant laryngeal tumor, especially in some developing countries where alcohol and smoking are the most common risk factors \[[@pone.0188322.ref002], [@pone.0188322.ref003]\]. Patients with supraglottic carcinoma often present with non-specific throat pain, dysphagia, and neck lymphadenopathy as the primary disease features. These patients tend to present for care at an advanced stage and have poor overall survival \[[@pone.0188322.ref004], [@pone.0188322.ref005]\]. The supraglottic laryngeal region includes the epiglottis, ventricular bands, aryepiglottic fold (laryngeal aspect), and laryngeal ventricle, each of which serves a distinct anatomic purpose \[[@pone.0188322.ref006]\]. Until now, it has been unclear whether clinical features and prognosis differ based on carcinoma subregion.

In this study, supraglottic carcinoma was divided into four sub-types based on subregion: epiglottis, ventricular bands, aryepiglottic fold (laryngeal aspect), and laryngeal ventricle. Differences in clinicopathologic characteristics, HPV presence, and survival were then compared by subregion.

Materials and methods {#sec006}
=====================

Clinical data {#sec007}
-------------

The clinicopathologic data were analyzed retrospectively for 111 patients with supraglottic squamous cell carcinoma who were diagnosed between January 1, 1995 and December 31, 2005 and were initially treated with surgery at Sun Yat-sen University Cancer Center / Panyu Central Hospital ([Table 1](#pone.0188322.t001){ref-type="table"}). We divided supraglottic squamous cell carcinomas into four types based on subregion: epiglottis, ventricular bands, aryepiglottic fold, and ventricle. The tumor location and diagnosis were established using clinical examination, fibro-laryngoscope, computed tomography, magnetic resonance imaging, intraoperative exploration, and postoperative histopathologic report. All patients underwent surgery for the primary lesion and selective or therapeutic neck dissection. Postoperative radiotherapy is advised in case of cartilage invasion, positive surgical margins, T3 or T4 tumors, advanced nodal disease (e.g. N2c/N3) with extracapsular invasion. Patients at high-risk for recurrence received post-operative radiotherapy based on NCCN (National Comprehensive Cancer Network) guidelines at a mean dose of 60 Gy (range, 40 Gy to 70 Gy). Three patients who developed distant metastases after surgery received chemotherapy with docetaxel, cisplatin, and fluorouracil. Clinicopathologic features are shown in [Table 1](#pone.0188322.t001){ref-type="table"}. Pathologic diagnosis of squamous cell carcinoma was confirmed by two experienced pathologists.

10.1371/journal.pone.0188322.t001

###### Univariate factors influencing prognosis of supraglottic squamous cell carcinoma.

![](pone.0188322.t001){#pone.0188322.t001g}

  Variable                       Epiglottis   Ventricular bands   Aryepiglottic fold   Ventricle of larynx   *P*
  ------------------------------ ------------ ------------------- -------------------- --------------------- -------
  **Sex**                                                                                                    
   Men                           25           22                  26                   33                    0.858
   Women                         2            1                   1                    1                     
  **Age**                                                                                                    
   \<60 years                    10           14                  14                   12                    0.184
   ≥60 years                     17           9                   13                   22                    
  **pT stage**                                                                                               
   T1                            2            0                   1                    1                     0.431
   T2                            9            11                  6                    11                    
   T3                            13           9                   11                   13                    
   T4                            3            3                   9                    9                     
  **pN stage**                                                                                               
   N0                            13           16                  17                   28                    0.119
   N1                            6            2                   6                    2                     
   N2                            8            5                   4                    4                     
   N3                            0            0                   0                    0                     
  **pTNM stage**                                                                                             
   Stage I                       2            0                   1                    1                     0.588
   Stage II                      5            8                   3                    11                    
   Stage III                     11           8                   13                   11                    
   Stage IV                      9            7                   10                   11                    
  **Histology grade**                                                                                        
   G1                            10           9                   6                    12                    0.260
   G2                            9            11                  14                   19                    
   G3                            8            3                   7                    3                     
  **Surgery type**                                                                                           
   Supraglottic laryngectomy     1            3                   1                    1                     0.000
   Horizontal hemilaryngectomy   12           1                   5                    0                     
   Vertical hemilaryngectomy     0            7                   0                    11                    
   Frontolateral laryngectomy    2            0                   0                    0                     
   Total laryngectomy            12           12                  21                   22                    
  **R1 resection**                                                                                           
   Yes                           5            5                   6                    6                     0.964
   No                            22           18                  21                   28                    
  **Treatment modality**                                                                                     
   S                             18           11                  17                   19                    0.532
   S+R                           9            12                  9                    13                    
   S+C                           0            0                   1                    2                     
  **Neck metastasis**                                                                                        
   Yes                           13           16                  17                   28                    0.042
   No                            14           7                   10                   6                     

S, Surgery; R, Post-operative radiation therapy; C, Post-operative chemotherapy; R1 resection was defined when the distance of the tumour from the resection margin was less or equal 1 mm.

All patients were provided informed consent at the time of diagnosis between January 1, 1995 and December 31, 2005 for study participation using medical records and clinicopathologic data. Written ethics approval was obtained from the Hospital Research Ethics Committee of Panyu Central Hospital and Sun Yat-sen University Cancer Center.

Detection of human papillomavirus using in situ hybridization {#sec008}
-------------------------------------------------------------

Formalin-fixed, paraffin-embedded tissue samples from 111 patients were sectioned serially at 5 mm thickness. After de-paraffinization, in situ hybridization (ISH) was used to detect HPV. Samples were hybridized with a biotinylated whole-genomic DNA probe mixture of HPV 16 and 18 (ISH-5121, Beijing Zhongshan Jingqiao Company, China). Cervical carcinoma was used as an ISH positive control and a reverse HPV probe in the hybridization mix was used as an ISH negative control. The experiments were performed from August 1, 2011 to December 31, 2011.

Follow-up {#sec009}
---------

Follow-up data were obtained by outpatient chart review and telephone interview during the period from the date of first treatment to December 31, 2013. The tumor-based end points included local-regional control, cancer-specific survival and overall survival.

Statistical analysis {#sec010}
--------------------

The data was analyzed using SPSS 16.0 software. Survival analysis was undertaken by Kaplan-Meier analysis; factors were compared using log-rank test, and multivariate analysis was carried out using Cox proportional hazards model (backwards-selection method). The relationship between different factors was analyzed using chi-square tests. *P* value less than .05 was considered statistically significant.

Results {#sec011}
=======

Clinicopathologic characteristics of supraglottic carcinoma subregions {#sec012}
----------------------------------------------------------------------

Lymph node metastasis rates were 48.1%, 69.6%, 63.0%, and 82.4%, respectively, for supraglottic squamous cell carcinomas of the epiglottis, ventricular bands, aryepiglottic fold, and ventricle. Although lymph node metastasis rates differed between subregions (*P* = .042), there were no correlations between subregion and age, sex, or histologic grade ([Table 2](#pone.0188322.t002){ref-type="table"}). The incidence of R1-resection was 14.4% (16/111).

10.1371/journal.pone.0188322.t002

###### Correlation between clinical factors and supraglottic squamous cell carcinoma subregions.
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  Variable                          χ^2^     *P*
  --------------------------------- -------- -------
  **Sex**                           0.764    0.858
  **Age**                           4.837    0.184
  **Histologic grade**              7.713    0.260
  **Surgery type**                  50.178   0.000
  **Treatment modality**            5.091    0.532
  **Neck lymph nodes metastasis**   8.815    0.042

HPV presence by supraglottic carcinoma subregion {#sec013}
------------------------------------------------

HPV was detected in 16 of 111 patients (14.4%) by ISH, but there was no correlation between HPV status and subregion ([Table 3](#pone.0188322.t003){ref-type="table"}). When HPV status was compared for each pair of subregions, only the aryepiglottic fold and ventricle differed (χ2 = 50.565, *P* \< .05).

10.1371/journal.pone.0188322.t003

###### Clinicopathologic features for 111 patients with supraglottic squamous cell carcinoma and human papillomavirus.
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  ------------------------------------------------------------------------------------
  Variable              Cases   HPV (-)\         HPV (+)\         *P*          
                                N = 95 (85.6%)   N = 16 (14.4%)                
  --------------------- ------- ---------------- ---------------- ----- ------ -------
  Subregions                                                                   0.082

   Epiglottis           27      23               85.2             4     14.8   

   Ventricular bands    23      19               82.6             4     17.4   

   Aryepiglottic fold   27      20               74.1             7     25.9   

   Ventricle            34      33               97.1             1     2.9    
  ------------------------------------------------------------------------------------

Local-regional control rate {#sec014}
---------------------------

At the last follow-up date of December 31, 2013, 67 patients had local-regional recurrence. Subgroups differed with respect to local-regional control rate (χ2 = 9.235, *P* = .026) ([Fig 1](#pone.0188322.g001){ref-type="fig"}). The local-regional control rates of carcinoma from epiglottis or ventricular bands was better than that of carcinoma from aryepiglottic fold or ventricle ([Fig 1](#pone.0188322.g001){ref-type="fig"}). Carcinoma subregion was correlated with local-regional recurrence ([Table 4](#pone.0188322.t004){ref-type="table"}).

![Local-regional control rate for patients with supraglottic squamous cell carcinoma, by subregion.](pone.0188322.g001){#pone.0188322.g001}

10.1371/journal.pone.0188322.t004

###### Local-regional control rate of 111 patients with supraglottic carcinoma.
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  Subregions           Cases   2-year (%)   5-year (%)   *P*
  -------------------- ------- ------------ ------------ -------
  Epiglottis           27      70.4         59.3         0.026
  Ventricular bands    23      78.3         78.3         
  Aryepiglottic fold   27      70.4         37.0         
  Ventricle            34      52.9         38.2         

Survival {#sec015}
--------

At the last follow-up date of December 31, 2013, seven patients were lost to follow-up, and all patients had been followed for at least 2 years (median, 64 months). The overall survival rate was 42.3%, and 43 patients experienced tumor relapse (10 in primary site, 26 in cervical lymph nodes, two in primary site plus cervical lymph nodes, and three in distant site). Subregions were correlated with overall survival ([Table 1](#pone.0188322.t001){ref-type="table"}). Subgroups differed with respect to cancer-specific survival (χ2 = 10.042, *P* = .018) and overall survival (χ2 = 10.526, *P* = .015) (Figs [2](#pone.0188322.g002){ref-type="fig"} and [3](#pone.0188322.g003){ref-type="fig"}).

![Cancer-specific survival for patients with supraglottic squamous cell carcinoma, by subregion.](pone.0188322.g002){#pone.0188322.g002}

![Overall survival for patients with supraglottic squamous cell carcinoma, by subregion.](pone.0188322.g003){#pone.0188322.g003}

Univariate analysis and multivariate analysis of prognostic factors {#sec016}
-------------------------------------------------------------------

To determine which factors affect survival of patients with supraglottic carcinoma, possible prognostic factors of sex, age, subregion, stage, histologic grade, lymph node metastasis, surgery type, and treatment modality were analyzed by univariate analysis and multivariate regression analysis. Results from the univariate analysis showed that subregion, pN spread, and TNM classification were significantly correlated with overall survival ([Table 5](#pone.0188322.t005){ref-type="table"}). Multivariate analysis results indicated that subregion and pTNM classification were independent prognostic factors affecting survival ([Table 6](#pone.0188322.t006){ref-type="table"}).

10.1371/journal.pone.0188322.t005

###### Factors influencing prognosis of patients with supraglottic squamous cell carcinoma.
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  Variables                            Cases   5-year overall Survival rates   χ^2^      *P*
  ------------------------------------ ------- ------------------------------- --------- -------
  **Sex**                                                                      0.498     0.48
   Men                                 106     41.5                                      
   Women                               5       60.0                                      
  **Age**                                                                      0.049     0.824
   \<60 years                          50      44.0                                      
   ≥60 years                           61      41.0                                      
  **Subregion**                                                                11.049.   0.012
   Epiglottis                          27      51.9                                      
   Ventricular bands                   23      60.9                                      
   Aryepiglottic fold                  27      25.9                                      
   Ventricle of larynx                 34      35.3                                      
  **pTstage**                                                                  7.325     0.062
   T1                                  4       75.0                                      
   T2                                  37      48.6                                      
   T3                                  46      41.3                                      
   T4                                  24      29.2                                      
  **pN stage**                                                                 8.614     0.013
   N0                                  74      45.9                                      
   N1                                  16      50.0                                      
   N2                                  21      23.8                                      
   N3                                  0       0                                         
  **pTNM stage**                                                               10.880    0.012
   Stage I                             4       75.0                                      
   Stage II                            27      51.9                                      
   Stage III                           43      46.5                                      
   Stage IV                            37      27.0                                      
  **Histology grade**                                                          0.557     0.757
   G1                                  37      43.2                                      
   G2                                  53      39.6                                      
   G3                                  21      47.5                                      
  **Surgery type**                                                             7.386     0.117
   Partial supraglottic laryngectomy   6       16.7                                      
   Horizontal hemilaryngectomy         18      50.0                                      
   Vertical hemilaryngectomy           18      61.1                                      
   Frontolateral laryngectomy          2       50.0                                      
   Total laryngectomy                  67      37.3                                      
  **Treatment modality**                                                       0.127     0.939
   Surgery                             65      43.1                                      
   Post-op RT treatment                43      41.9                                      
   Post-op chemotherapy                3       33.3                                      
  **Neck lymph nodes metastasis**                                              2.961     0.085
   Yes                                 37      35.1                                      
   No                                  74      45.9                                      

10.1371/journal.pone.0188322.t006

###### Factors influencing prognosis of supraglottic squamous cell carcinoma in multivariate analysis.
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  Factors         B       SE      Wald    *P*     Exp (B)   95.0% CI for Exp (B)
  --------------- ------- ------- ------- ------- --------- ----------------------
  **pTNM**        0.455   0.199   5.216   0.022   1.576     (1.067--2.329)
  **Subregion**   0.265   0.131   4.075   0.044   1.304     (1.008--1.687)

Discussion {#sec017}
==========

This study showed no differences with respect to patient age or sex, tumor histologic grade, or treatment modality and supraglottic carcinoma subregion. However, prognosis was better for patients with carcinoma of the epiglottis and ventricular bands compared to the aryepiglottic fold or ventricle, with survival rates of 51.9%, 60.9%, 25.9%, and 35.3%, respectively (*P* = .012). Because epiglottal and ventricular band carcinoma tend to grow anteriorly or downward and do not invade deep tissues until late in the disease, patients with these tumors may have better survival.

The supraglottic laryngeal region includes the epiglottis, ventricular bands, aryepiglottic fold (laryngeal aspect), and laryngeal ventricle, each of which serves a distinct anatomic purpose. For the purpose of tumor resection and function preservation, the surgical methods for carcinoma in each subregion is different, therefore, there appeared differences in the baseline distribution of surgical method between the different subregions, however, that might not lead to statistical bias. Patients with carcinoma of the epiglottis or aryepiglottic fold commonly undergo resection by horizontal hemi-laryngectomy or total laryngectomy, whereas those with carcinoma of the ventricular band or ventricle carcinoma usually undergo vertical hemi-laryngectomy or total laryngectomy \[[@pone.0188322.ref007]--[@pone.0188322.ref009]\]. There is a relatively wider space for epiglottal tumor growth before invasion to other subregions; thus, successful resection may be more feasible. Because the ventricular band and ventricle subregions are more limited in size, carcinomas in these two subregions may extend earlier in the longitudinal direction. Most patients with ventricular band or ventricle carcinoma had a poor prognosis, with stage III (43 of 111) or stage IV (37 of 111) disease at diagnosis. In this study, subgroups differed with respect to local-regional control rate (*P* \< .05). The local-regional control rates of carcinoma in epiglottis or ventricular bands was better than that in aryepiglottic fold or ventricle, therefore, carcinoma in different subregions might present different local-regional rate after treatment.

There were also differences in neck lymph node metastasis rates between supraglottic carcinoma subregions (*P* = .045). Carcinomas of the aryepiglottic fold (37.0%) and epiglottis (51.9%) more often metastasized to neck lymph nodes than did carcinomas of the ventricular bands (30.4%) or ventricles (17.6%); this spread is due to the higher density of micro-lymphatic nets in aryepiglottic fold and epiglottis than that in the ventricular bands or ventricles.

As reported previously, HPV detection rates range from 26% to 44% in laryngeal cancers \[[@pone.0188322.ref010]\]. HPV 16 and 18 are detected at high levels in head and neck squamous cell carcinomas. HPV 16 accounts for 86.7% of the HPV-positive oropharyngeal squamous cell carcinomas, whereas HPV 18 accounts for only 2.9%. For HPV-positive oral squamous cell carcinomas, HPV 16 is found in 68.7% and HPV 18 is found in 34.5%. In all the HPV-positive laryngeal cancer cases, HPV 16 is detected in 69.2% of the cases and HPV 18 is detected in 17.2% of the cases. HPV-positivity rates are lower for squamous cell carcinomas of other areas of the head and neck \[[@pone.0188322.ref011]\].

HPV expression levels also differ by laryngeal subregion. Almadori et al found the HPV-positivity rate to be much higher in supraglottic carcinoma compared to other laryngeal areas \[[@pone.0188322.ref012]\]. For HPV-positive laryngeal squamous cell carcinoma, positivity rates are 60.6%, 36.4%, and 3.0% for the supraglottic, glottic, and subglottic regions, respectively \[[@pone.0188322.ref013]\]. HPV infection may be significantly correlated with laryngeal carcinoma subregion but not with clinical stage, lymph node metastasis, or tumor grade \[[@pone.0188322.ref013]\]. In our research, HPV expression was 14.7%; however, HPV expression was higher in ventricular band (25.9%), epiglottis (14.8%), and aryepiglottic fold (17.4%) carcinoma compared to ventricle carcinoma (2.9%). HPV expression differed between aryepiglottic fold and ventricle carcinoma (*P* = .008). Compared to ventricle carcinoma, other areas had higher HPV detection rates; those three subregions are nearer to the oropharynx, where carcinomas tend to have higher HPV expression rates \[[@pone.0188322.ref014]\]. Because supraglottic carcinomas require different surgical approaches based on subregion, HPV positivity, and prognosis, these tumors should be categorized by subregion to individualize therapy.

Demographic and clinical characteristics have been studied extensively with respect to prognosis of laryngeal carcinoma. As with previous studies, \[[@pone.0188322.ref004], [@pone.0188322.ref015], [@pone.0188322.ref016]\] demographic data such as age and sex were not associated with prognosis in our study. Raitiola and colleagues showed that T stage and cervical lymph node metastases are independent prognostic factors for laryngeal carcinoma \[[@pone.0188322.ref017]\]. Likewise, Santos et al found that T stage, N stage, clinical stage, and extracapsular lymph node spread were related to prognosis, with lymph node metastases independently affecting prognosis \[[@pone.0188322.ref018]\]. Similarly, Vlachtsis et al showed that T stage, N spread, TNM classification, and tumor site affect prognosis, with TNM classification independently predicting prognosis \[[@pone.0188322.ref019]\]. However, no studies to date have evaluated the significance of laryngeal carcinoma subregions in prognosis. In our study, carcinoma subregion, pN spread, and pTNM classification had prognostic significance in univariate analysis, with subregion and pTNM classification as independent predictors of prognosis.

Our study showed that different subregions of supraglottic carcinoma were associated with distinct clinical features such as HPV expression, lymph node metastasis rate, local-regional control and prognosis. Therefore, supraglottic squamous cell carcinoma should be considered as distinct subtypes corresponding to their subregions of origin so that patients can receive individualized therapy. However, some risk factors like alcohol and smoking are not included in the analysis due to the incomplete data, which may affect the results, and the number of cases in this study is relatively small, further studies would be needed to confirm that different subregions of supraglottic carcinoma show distinct clinical features.

Supporting information {#sec018}
======================

###### Data subtype brief for PLOS 2011.

(XLSX)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
